LBH Phase II in Small Cell Lung Cancer (SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2010

Conditions
Small Cell Lung Carcinoma
Interventions
DRUG

LBH581

25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.

Trial Locations (8)

10126

Az. San. Ospedaliera Molinette S. Giovanni Battista di Torino, Torino

16132

Istituto Nazionale Ricerca sul Cancro, Genova

34125

Klinikum Kassel Innere Medizin, Kassel

43100

Ospedale Maggiore di Parma, Parma

60488

Klinik für Onkologie und Haematologie, Frankfurt am Main

83100

"Azienda Ospedaliera S. G. Moscati", Avellino

90141

U.O. di Oncologia Medica, Palermo

00151

Azienda Ospedaliera San Camillo Forlanini, Rome

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Southern Europe New Drug Organization

OTHER